MFMikhail Yu. Fedyanin

Mikhail Yu. Fedyanin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mikhail Yu. Fedyanin has a total of 930 co-authors. Here are the top co-authors by number of shared publications:

  • Alexey A. Tryakin

    N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

    65 shared publications
  • Sergei A. Tjulandin

    N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

    35 shared publications
  • М. Ю. Федянин

    ГБУЗ «Московский многопрофильный клинический центр «Коммунарка» Департамента здравоохранения г. Москвы»; ФГБУ «Научный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России

    35 shared publications
  • Ilya A. Pokataev

    Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health

    28 shared publications
  • Liudmila G. Zhukova

    Loginov Moscow Clinical Scientific Center, 111123 Moscow, Russia

    16 shared publications
  • Daniil Stroyakovskiy

    Moscow City Oncology Hospital No. 62

    15 shared publications

Latest Publications

  • Open Access

    Search for prognostic factors when prescribing immunotherapy in the second line of treatment for metastatic gastric cancer

    by N. N. Semenov, M. Yu. Fedyanin, L. G. Zhukova, Н. Н. Семёнов, М. Ю. Федянин, Л. Г. Жукова

    Introduction. It has been previously reported that the effectiveness of therapy with immune checkpoint inhibitors (ICI) in the second line of metastatic gastric cancer was not higher than with cytostatic therapy, and did not depend on the level of PD-L1 CPS and the presence of MSI. At the same time, 28 % of patients lived more than 2 years after starting therapy. Aim . To identify the criteria for predicting overall survival (OS) in patients receiving second-line ICI therapy. Materials and methods . We assessed 91 patients with morphologically confirmed metastatic gastric or cardioesophageal junction cancer who progressed during the 1st line of treatment and received ICI therapy in the 2nd line. The median follow-up time was 54.2 months (28–90 months). Patient characteristics : 53.8 % of patients were males; average age — 65.7 years (34.1–85.7); ECOG 2 performance status in 9.9 %; synchronous metastases — 56 %; liver / peritoneum metastases — 69.3 %; metastases in 3 or more organs — 17.6 %; CPS > 10–41.8 %; MSI — 43.5 %. Results. A univariate analysis which included 22 indicators showed a negative effect on OS after 1st line therapy with PFS < 8 months, LDH level > 248 U / L, neutrophil / lymphocyte ratio (NLR) < 2.35, platelet / neutrophil ratio (PNR) > 168.7. In multifactorial analysis, significance was stated for the 1st line with PFS > 8 months (HR 3.541; 95 % CI 1.186–10.576, p = 0.024) and LDH level < 248 U / l (HR 4.606; 95 % CI 1.847–11.484, p = 0.001). When assessing long-term outcomes in patients with or without risk factors, we found that in the absence of negative prognostic factors the mPFS was 19.7 months, while in the presence it was only 3.4 months (HR 3.47; 95 % CI 1.2–10.03, p = 0.022). The OS was 33.4 months and 5.4 months. (HR 4.028; 95 % CI 1.376–11.793, p = 0.011), respectively. When comparing these groups by their main characteristics, we noticed that there were no differences in ECOG status, the number of organs with metastases, the frequency of CPS ≥ 10 and MSI. Conclusions. The results obtained leave a reasonable assumption that a group of patients on the 1st line had PFS > 8 months and a normal baseline LDH level. And they had real benefits from ICI therapy with the 2nd line therapy for metastatic gastric cancer. However, a more accurate validation requires a prospective study.

  • Open Access

    Depth filtration coupled with proteomics identifies colorectalcancer-specific extracellular vesicle protein corona as potential biomarker

    by Ekaterina Moiseeva, Anna Bugrova, Yulia Shevtsova, Elena V. Svirshchevskaya, Alexander Yakovlev, Elizaveta Polyanskaya, Mikhail Yu. Fedyanin, Mikhail Ivanov, Denis Silachev, Alexey Kononikhin, et al.

    The clinical translation of extracellular vesicle (EV)-based diagnostics remains hindered by the lack of rapid, non-degradative, and scalable isolation methods compatible with robust biomarker discovery. In this study we use express asymmetric depth filtration method and compare it directly with ultrafiltration coupled with size-exclusion chromatography for EV isolation from two colorectal cancer cell lines, HCT116 and HT29. The two methods yield distinct EV subpopulations, with depth filtration providing faster processing and good purity suitable for proteomics. Using depth filtration, we performed comparative proteomic profiling of EVs from CRC, ovarian (SKOV3), and breast (SKBR3) cancer cell lines to identify candidate CRC-associated protein markers. To assess clinical relevance, we then isolated EVs from the blood plasma of healthy donors and stage III CRC patients using depth filtration and analyzed their proteomes. Six proteins were overexpressed in both CRC cell line EVs and plasma-derived CRC EVs relative to the other cancer types and healthy controls. Three of these six proteins – fibrinogen gamma, fibronectin, and vitronectin, each of which is a surface EVs protein – were validated by ELISA in an independent cohort (12 CRC patients, 8 healthy donors), confirming their elevated expression on CRC patient plasma EVs. Notably, EV-associated protein levels showed better stage discrimination (stage I–II vs. III–IV) than total plasma protein levels. These findings demonstrate that depth filtration enables rapid, clinically compatible EV isolation and that comparative proteomics of cell line and plasma EVs can identify robust, stage-sensitive CRC biomarkers for liquid biopsy development.

  • Open Access

    Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer. A retrospective study

    by Olesia A. Stativko, Стативко Олеся Алексеевна, Irina A. Shangina, Шангина Ирина Александровна, Nikita M. Starostin, Старостин Никита Максимович, Ilya A. Pokataev, Покатаев Илья Анатольевич, Alexey A. Rumyantsev, Румянцев Алексей Александрович, et al.

    Aim. To investigate the predictive value of baseline erythroblasts in selecting patients with metastatic hormone-sensitive prostate cancer (mHSPC) for triplet therapy. Materials and methods. We provided a multicenter retrospective study that included patients treated between 2022 and 2024 for high-volume mHSPC according to CHAARTED criteria who received either doublet [androgen deprivation therapy (ADT) + an androgen receptor pathway inhibitor (ARPI)] or triplet (docetaxel + ADT + ARPI) therapy. The primary endpoint was 2-year progression-free survival (PFS), defined as time from treatment initiation to clinical or radiological progression, initiation of new systemic therapy, or death from any cause. Cardinality matching at a 2:1 ratio was performed to balance potential confounding variables. Results. A total of 234 patients were included (141 triplet, 93 doublet). After matching, 122 patients remained in the triplet group and 61 in the doublet group. With a median follow-up of 23.5 months for the triplet group and 33.9 months for the doublet group, 2-year PFS rates were 71.9 and 57.8%, respectively (HR 0.62, 95% CI 0.40–0.95; p=0.027). Subgroup analysis demonstrated significantly greater survival benefit from triplet therapy in patients with detectable baseline erythroblasts (PFS: HR 0.29, 95% CI 0.11–0.76; OS: HR 0.24, 95% CI 0.07–0.77) compared to those without erythroblasts (PFS: HR 0.66, 95% CI 0.37–1.19; OS: HR 0.52, 95% CI 0.26–1.06). Conclusion. The baseline presence of circulating erythroblasts serves as a strong predictive marker for benefit from docetaxel intensification in patients with high-volume mHSPC. This readily available biomarker may guide patient selection for triplet therapy, pending prospective validation.

  • Open Access

    Options for the third and subsequent lines of drug treatment for patients with metastatic colorectal cancer. A review

    by Mikhail Yu. Fedyanin, Федянин Михаил Юрьевич

    Despite advancements in molecular genetic profiling and the development of new antitumor pharmacotherapies, treatment options for individuals with metastatic colorectal cancer remain restricted, with median overall survival (OS) ranging from 16 to 34 months, contingent upon the clinical context. In this patient population, the majority begin first-line therapy; approximately 80% receive second-line treatment; and around 40–60% progress to third-line therapy. The substantial number of patients eligible for further antitumor treatment after two lines underscores the need to examine the selection of third- and subsequent-line therapy. This review consolidates current approaches to selecting third- and subsequent-line treatments for patients with refractory metastatic colorectal cancer, including regorafenib, fruquintinib, and trifluridine/tipiracil in both monotherapy and combination regimens. The narrative review incorporates findings from randomized Phase III trials (CORRECT, CONCUR, FRESCO/FRESCO-2, RECOURSE, SUNLIGHT, TASCO1/6), real-world practice registries (CONSIGN, PRECONNECT), network meta-analyses, and ongoing clinical trials (ClinicalTrials.gov, data current to March 2026). The literature review indicates that regorafenib, fruquintinib, and FTD/TPI demonstrate superior efficacy compared with placebo when combined with best supportive care. Notably, the combination of FTD/TPI with bevacizumab yields the most favorable OS, with a median of 10.8 months and a relative risk of 0.61. Network meta-analyses rank FTD/TPI with bevacizumab as optimal for OS (SUCRA 0.92). However, assessments of individual subgroups suggest that certain drugs may be more advantageous in specific contexts. The selection of third-line therapy requires a personalized approach that considers mutational status, tumor location, prior treatments, and tolerability. The combination of FTD/TPI with bevacizumab appears to be the most promising treatment option; however, direct comparisons with regorafenib and fruquintinib are warranted.

  • Prognostic significance of KRAS, NRAS, and BRAF mutations in patients with colorectal cancer and liver metastases: results of a single-center retrospective study

    by Georgii G. Makiev, Макиев Георгий Георгиевич, Mikhail Yu. Fedyanin, Федянин М. Ю., Rukiyat Sh. Abdulaeva, Абдулаева Р. Ш., Sofiya I. Polyanskaya, Полянская С. И., Aleksey E. Kalinin, Калинин А. Е., et al.

    Background. The significance of specific mutation variants, particularly rare ones, in patients with colorectal cancer (CRC) and isolated liver metastases is insufficiently studied, while the possibility of achieving resectability is critical in the context of prognosis and survival. Aim. To assess the prognostic significance of various mutations in the KRAS, NRAS, and BRAF genes in patients with CRC. Materials and methods. The study included 366 patients with CRC and isolated liver metastases. Group 1 (n = 198) included patients with mutations in KRAS, NRAS, BRAF (Mut) genes, and Group 2 (n = 168) included those without activating mutations (wild-type – wt). Progression-free survival (PFS), risk of progression, rate and chance of achieving resectability were assessed. Results. Group 1 showed worse outcomes compared to Group 2: a lower rate of liver resection (36.9 % vs 49.4 %; p = 0.016) and a shorter median PFS (10.3 vs 12.9 months; hazard ratio 1.57 [95 % confidence interval 1.24–1.99; p 0.001). Significant heterogeneity was revealed among Mut patients. The worst prognosis was associated with KRAS G12D mutations (median PFS 5.9 months; hazard ratio 2.99 [95 % confidence interval 2.08–4.3; p 0.001), as well as G12C, G12A, and BRAF mutations. However, performing liver resection improves long-term outcomes even in this patient subgroup. In contrast, patients with KRAS G13D mutations and rare A146 / K117 / Q61 mutations demonstrated significantly better long-term outcomes and a high rate of resectability. Conclusion. This study evaluates the prognostic value of RAS / BRAF mutations in patients with CRC and isolated liver involvement. These findings are essential for patient stratification in the current era of personalized therapy.

  • Open Access

    Comparative assessment of diagnostic value of microRNAs for detection of colorectal cancer in adults: results of systematic review and network meta-analysis

    by E. A. Grivachev, Гривачев Е. А., A. A. Tryakin, Трякин А. А., S. V. Vinokurova, Винокурова С. В., K. V. Sapozhnikov, Сапожников К. В., E. S. Obarevich, Обаревич Е. С., et al.

    Background. Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and early detection is crucial for improving patient outcomes. Circulating microRNAs have emerged as promising non-invasive biomarkers; however, comparative evaluation of their diagnostic performance, particularly in combination panels, remains limited. Aim. To compare the diagnostic value of circulating microRNAs and their combinations for early colorectal cancer detection in adults using network meta-analysis approach. Materials and methods. A systematic review and network meta-analysis of studies identified through the PubMed and Embase databases was conducted. The primary outcomes included the area under the ROC curve (AUC), sensitivity, specificity, accuracy, and surface under the cumulative ranking curve (SUCRA). Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Statistical analyses were performed using the R software environment. Results. The included studies demonstrated substantial methodological and clinical heterogeneity (predominance of case – control design, variability in sample types and cohort characteristics), accompanied by high statistical heterogeneity in the network for AUC (I2 = 74.8 %). According to the network comparison, the most promising single biomarkers were miRNA-760 and miRNA-221, which achieved the highest SUCRA rankings (0.773 and 0.753, respectively). The most extensively studied miRNA-21 showed intermediate performance (SUCRA = 0.677). The highest diagnostic performance was observed for multi-biomarker panels: miRNA-21 + miRNA-25 + miRNA-18a + miRNA-22 (0.888), miRNA-21 + miRNA-92a + miRNA-221 (0.797), and miRNA-21 + miRNA-221 + miRNA-150 (0.797). Conclusion. Circulating microRNAs represent a promising approach for non-invasive early detection of colorectal cancer. The most relevant candidates include miRNA-760, miRNA-221, and high-performing microRNA panels. Clinical implementation requires further prospective clinical validation and standardization of the analytical methods.

  • Open Access

    Identification of microRNA biomarkers for the early detection and differential diagnosis of colorectal cancer

    by Evgeny A. Grivachev, Гривачев Евгений Александрович, M. D. Fedorova, Федорова М. Д., N. V. Elkina, Елкина Н. В., S. V. Vinokurova, Винокурова С. В., O. V. Morozova, Морозова О. В., et al.

    Introduction. Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality in both men and women. Early detection is crucial for improving patient outcomes; however, currently available screening methods are often invasive and demonstrate suboptimal diagnostic accuracy, limiting their applicability in the general population. In recent years, microRNAs (miRNAs) have attracted considerable attention as promising biomarkers for early CRC detection, with potential clinical implementation that may contribute to reduced mortality. Aim. To analyze miRNA expression in tissues of patients with colorectal cancer and colorectal adenomas in order to identify promising biomarkers for the development of diagnostic tools for CRC. Materials and methods. The study was performed using archival formalin-fixed paraffin-embedded colon tissue samples. Total RNA, including small RNAs, was isolated following enrichment of the target epithelium by microdissection. Expression levels of miR-21-5p, -23a-3p, -92a-3p, -17-5p, -451a, -1246, 135b-5p, and the reference -210-3p were analyzed using the stem-loop detection method. Relative expression was calculated using the –ΔΔCt method. Statistical significance of intergroup differences was assessed using the Mann–Whitney U test, while diagnostic performance was evaluated by ROC analysis with calculation of area under the curve (AUC), sensitivity, and specificity. Results. MiR-17-5p, -21-5p, -92a-3p, -135b-5p, and -1246 demonstrated high diagnostic potential, with expression levels significantly elevated in adenomas and adenocarcinomas compared with conditionally normal epithelium. MiR-17-5p was of particular interest, as its intermediate expression level in adenomas suggests involvement in the early stages of tumor progression. In ROC analysis, miR-17-5p demonstrated high sensitivity and specificity both for differentiating CRC from normal tissue and for distinguishing adenomas from adenocarcinomas. In addition, miR-17-5p and miR-23a-3p effectively differentiated adenomas from both normal and tumor tissues. Conclusion. The identified miRNAs, particularly miR-17-5p, -21-5p, -92a-3p, -135b-5p, and -1246, represent a promising basis for the development of diagnostic miRNA panels. Further investigation of tissue and extracellular levels of these miRNAs may facilitate the development of minimally invasive diagnostic and monitoring tests for CRC and colorectal adenomas, as well as enable evaluation of the prognostic significance of these biomarkers.

  • Open Access

    Choice of the 3rd and the 4th line therapy sequence in patients with metastatic colorectal cancer

    by G. M. Naydin, G. G. Makeev, D. A. Barsova, F. V. Moiseenko, A. B. Rays, M. Yu. Fedyanin, A. P. Chernova, V. I. Evdokimov, L. G. Zhukova, D. L. Stroyakovsky, et al.

    Introduction : Treatment options in the third line for patients with metastatic colorectal cancer are limited in the Russian Federation to the multikinase inhibitor regorafenib and the strategy of re-administering previously effective chemo-targeted therapy (hereinafter referred to as chemotherapy re-challenge). Aim : To evaluate the efficacy and safety of regorafenib and chemotherapy re-challenge in later lines of therapy for metastatic colorectal cancer, and to identify patient subgroups deriving the greatest clinical benefit from the upfront choice of each approach. Materials and methods: A multicenter retrospective study was conducted (four oncology institutions in the Russian Federation, 2010–2021). A total of 218 patients with metastatic colorectal cancer after progression on fluoropyrimidines, oxaliplatin, and irinotecan were included; they received regorafenib or chemotherapy re-challenge in the 3rd and / or 4th line. All patients had 4‑th line of treatment. The primary endpoint was median progression-free survival in the 3rd line; secondary endpoints included median progression-free survival in the 4th line, median overall survival, and toxicity (CTCAE v5.0). Survival was analyzed using the Kaplan — Meier method with the logrank test; subgroup analyses were performed according to clinical and prognostic factors. Results : Chemotherapy re-challenge was administered to 121 patients (55.5 %) and regorafenib to 97 (44.5 %); median age was 63 and 62 years, respectively (p = 0.41). Median overall survival was higher with chemotherapy re-challenge: 19.05 months versus 13.6 months (HR = 0.60; 95 % CI 0.43–0.83; p < 0.01). Median progression-free survival in the 3rd line was also higher in the chemotherapy re-challenge group: 6.06 versus 3.02 months (HR = 0.58; 95 % CI 0.44–0.76; p < 0.01). In the 4th line, no statistically significant differences in median progression-free survival were observed: 3.7 vs 2.87 months (HR = 0.78; 95 % CI 0.59–1.04; p = 0.09). Subgroup analyses showed an overall survival and / or progression-free survival advantage for chemotherapy re-challenge across all prognostic groups. Chemotherapy re-challenge was associated with a more favorable toxicity profile. Dose reduction of regorafenib was required in approximately 40 % of patients, and treatment discontinuation due to toxicity occurred in 8–10 %. Conclusion : In a selected cohort of patients able to receive subsequent lines of therapy, third-line chemotherapy re-challenge was associated with longer overall survival and progression-free survival compared with regorafenib.

  • Open Access

    Comparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice

    by Evgeniya S. Kuzmina, Mikhail I. Fedyanin, Polina S. Feoktistova, Marina A. Lyadova, Denis S. Fedorinov, Olga R. Magamedova, Sergey A. Parts, Maxim A. Polyanskiy, Egor P. Fekhtel, Ilya A. Pokataev, et al.

    Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.

  • Open Access

    Analysis of the efficacy and safety of regorafenib versus chemotherapy retreatment in 3rd line treatment of metastatic colorectal cancer

    by Grigoriy M. Naydin, D. А. Barsova, F. V. Moiseenko, A. B. Rays, M. Yu. Fedyanin, A. P. Chernova, V. I. Evdokimov, L. G. Zhukova, D. L. Stroyakovskiy, R. Sh. Abdullaeva, et al.

    Introduction. Therapeutic options for 3rd-line treatment of metastatic colorectal cancer (mCRC) include chemotherapy retreatment with previously used regimens and regorafenib. Due to the lack of phase III prospective studies and conflicting retrospective results, we performed a comparative analysis of the efficacy and safety of chemotherapy ± targeted therapy retreatment versus regorafenib in a large patient cohort. Materials and methods. The study included mCRC patients from 4 oncology centers in the Russian Federation treated between 2010 and 2021 who received 3rd-line therapy either with chemotherapy ± targeted agents (epidermal growth factor receptor or vascular endothelial growth factor antibodies) (CTT group) or with regorafenib. The primary endpoint was 9-month overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR) and toxicity. Univariable and multivariable analyses were conducted to identify prognostic factors. Results. A total of 334 patients were included. Median follow-up was 30.3 months (95 % confidence interval (CI) 26.0–34.5) in the CTT group and 23.8 months in the regorafenib group. The groups differed in several baseline characteristics: primary tumor resection was performed more frequently (76.1 % versus 67.6 %; p = 0.088) and ECOG 0 status was more common (25.2 % versus 14.2 %; p = 0.006) in the CTT group. Patients treated with regorafenib more frequently had elevated carcinoembryonic antigen ≥50 ng / mL (45.3 % versus 65.3 %; p 0.001) and indolent disease course ≥20 months (64.3 % versus 49.1 %; p = 0.005), while a «treatment-free interval» ≥6 months after oxaliplatin or irinotecan was observed less frequently (68.1 % versus 43.3 %; p 0.001). Chemotherapy retreatment demonstrated a statistically significant advantage in median OS (18.1 months versus 10.2 months; hazard ratio (HR) 0.51; 95 % CI 0.39–0.67; p 0.0001) and PFS (6.0 month versus 2.8 months; HR 0.54; 95 % CI 0.43–0.67; p 0.0001). ORR was 6.1 % in the CTT group compared to 0.6 % in the regorafenib group. In multivariable analysis, unfavorable prognostic factors were worse ECOG status (ECOG 1: HR 1.77; p = 0.002; ECOG 2: HR 2.56; p = 0.001), right-sided primary tumor location (HR 1.98; p 0.001), presence of ≥2 liver metastases (HR 1.52; p = 0.021), absence of radical resection of the primary tumor (HR 1.91, 95 % CI 1.32–2.78; p = 0.001), shorter interval between 1st-line and 3rd-line therapy (a longer course 20 months correlated with better prognosis: HR 1.38, 95 % CI 1.04–1.85; p = 0.028), and carcinoembryonic antigen ≥50 ng / mL (HR 1.38, 95 % CI 1.04–1.82; p = 0.026). Based on these factors, a prognostic model was created that identifies favorable (median OS 19.4 months), intermediate (median OS 13.0 months), and poor (median OS 6.6 months) risk groups. The C-index was 0.698 (standard error 0.02). Conclusion. Chemotherapy retreatment showed superiority over regorafenib in 3rd-line treatment of mCRC. Its higher efficacy was confirmed across all prognostic subgroups. Predictive analysis did not identify any subgroup with advantage from regorafenib therapy.